19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Digital metastasis of tongue squamous cell carcinoma

      case-report
      , MD
      JAAD Case Reports
      Elsevier
      digit metastasis, nail change, oncologic patient, squamous cell carcinoma, tongue

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Nail disorders are common complications in oncologic patients who have received chemotherapy.1, 2, 3, 4 The all-grade incidence of nail changes with paclitaxel treatment has been reported to be 43.7%. 3 Nail characteristics can be divided into anatomic sites—nail matrix (Beau's line, onychomadesis), nail bed (onycholysis, pigmentation changes), and nail fold (paronychia, pyogenic granuloma). This study reports a patient with advanced squamous cell carcinoma of the tongue who had nail changes on the left index finger after treatment with taxane chemotherapy and an epidermal growth factor receptor inhibitor. Case report A 61-year-old man had squamous cell carcinoma (SCC) at the base of the tongue (clinical stage III, T3, N1, M0) diagnosed 2 years previously. He received multiple courses of chemotherapy (cisplatin based), but his disease progressed. The SCC had metastasized to his bones, liver, and lungs. He then received second and third lines of treatment with targeted therapy (afatinib) and chemotherapy (paclitaxel). He was also treated with adjuvant radiation. During treatment with targeted therapy, he experienced grade II paronychia of the fingernails with spontaneous resolution. He presented with a 2-week-old painful, red lesion on the left index finger with a history of spontaneous bleeding within the first 4 days. Two months earlier, he received the last course of paclitaxel chemotherapy. A physical examination of the left index finger found a tender, ill-defined erythematous patch with a firm consistency on the radial side of the lateral nail fold and one-third of the adjacent subungual tissue (Fig 1). The differential diagnosis included infection, particularly bacterial infection, pyogenic granuloma, and metastasis of SCC. Gram stain was negative. A plain radiograph of both hands (anteroposterior view) showed a well-defined osteolytic lesion at the radial side of the distal phalanx (Fig 2). A skin biopsy found multiple fragments of squamous epithelial cells with some prominent nucleoli, mitosis, and foci of keratinization (Fig 3). The diagnosis was digital metastasis of squamous cell carcinoma, and the patient was treated with supportive care. He died 5 days after the diagnosis of the digital metastasis. Fig 1 Appearance of the nail change. Fig 2 Plain radiograph of both hands shows bone lesion at distal phalanx on the left index. Fig 3 Hematoxylin-eosin staining of the skin biopsy specimen shows well-differentiated squamous cell carcinoma. (Original magnification: ×40.) Discussion Nail changes commonly occur in patients who receive taxane chemotherapy and treatment with epidermal growth factor receptor inhibitors.3, 4, 5, 6 The physician should be attentive to nail changes occurring on a few or multiple nails which develop from common types of chemotherapy and improve after cessation of therapy. In this case report, the patient's nail condition possibly mimicked nail change from chemotherapy or a pyogenic granuloma-like lesion. However, the patient had only single fingernail involvement with persistent symptoms after cessation of chemotherapy. Fingers are a rare site for metastasis with no exact incidence rate. In a large review of 221 cases of over 27 years, it was found that cancers metastasize to the hand and wrist more commonly in males than females. 7 The most common presentations are redness and pain, but the symptoms can also develop with a mass, such as a pyogenic granuloma-like lesion. 8 Clinical signs are easily mistaken for infections and inflammation such as felon, paronychia, pyogenic granuloma, or rheumatoid arthritis. 9 The distal phalanx of the thumb is the most common site of involvement.7, 9 Malignancies of the lung, gastrointestinal tract, and kidney are often the primary tumors.7, 8, 9 Metastases to the fingers and hands are most commonly from malignancy of the lung, whereas metastases to the toes and feet is most frequently from the genitourinary tract. 10 To our knowledge, there are no previous reports of this condition stemming from a primary tumor of the tongue. Radiographic and histopathologic studies can be useful for diagnosis. The plain radiograph could show spotting osteolysis and periosteal bone reaction. 8 The pathologic results are relatable and consistent with the primary tumor. There is no standard management of digital metastases. Surgical treatments including excision, curettage, and amputation are the treatments of choice.8, 9 There is no survival outcome study in cases of patients with digital metastasis. However, this condition is associated with a poor prognosis of an advanced primary tumor. Digital metastasis is a rare condition. To our knowledge, this is the first case of digital metastasis from squamous cell carcinoma of the tongue. This report points to the need for dermatologists to consider a possible diagnosis of digital metastasis with a high index of suspicion.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Dermatological adverse events with taxane chemotherapy.

          Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.

            Chemotherapy-induced hand-foot syndrome and nail changes are common complications of many classic chemotherapeutic agents and the newer molecular targeted therapies. They significantly impact patient quality of life, and frequently necessitate chemotherapy dose intensity modification or reduction. We aim to describe the epidemiology, pathogenesis, clinical presentation, and current evidence-based treatment options for these entities.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.

              Targeted drugs are increasingly being used for cancer management. They are designed to block specific cancer cell processes, and are often better tolerated than conventional chemotherapeutic drugs. Cutaneous reactions, however, are not uncommon, because some target molecules are also present in the skin. Tyrosine kinase inhibitors can cause edema and macular rash, whereas papulopustular rash, paronychia, regulatory changes in hair, itching, and dryness caused by epidermal growth factor receptor inhibitors (PRIDE) syndrome can be seen in patients treated with these drugs. Vismodegib may result in muscle spasms and alopecia. Multiple rashes can be seen with bortezomib, while sunitinib and sorafenib cause hand-foot skin reactions. New melanoma therapies, such as ipilimumab, cause immune-related adverse events of dermatitis and pruritus, while BRAF inhibitors can produce exanthematous rash and lead to an increased risk of squamous cell carcinoma. Dermatologists should be aware of these new therapies and their cutaneous reactions to be able to provide appropriate care and management for cancer patients.
                Bookmark

                Author and article information

                Contributors
                Journal
                JAAD Case Rep
                JAAD Case Rep
                JAAD Case Reports
                Elsevier
                2352-5126
                02 February 2018
                March 2018
                02 February 2018
                : 4
                : 2
                : 200-202
                Affiliations
                [1]Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
                Author notes
                []Correspondence to: Kumpol Aiempanakit, MD, Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand, 90110. akumpol@ 123456medicine.psu.ac.th
                Article
                S2352-5126(17)30215-1
                10.1016/j.jdcr.2017.09.009
                5993555
                16b34d14-f90a-4fe9-b49c-97812e3a7902
                © 2017 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                digit metastasis,nail change,oncologic patient,squamous cell carcinoma,tongue

                Comments

                Comment on this article